CKD-731

[1]. Chun E, et al. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. International journal of cancer. 2005 Mar 10;114(1):124-30. [Content Brief]

[2]. Fardis M, et al. Design, synthesis and evaluation of a series of novel fumagillin analogues. Bioorganic & medicinal chemistry. 2003 Nov 17;11(23):5051-8.

[3]. Kwon HJ, et al. Chemical genomics-based target identification and validation of anti-angiogenic agents. Current medicinal chemistry. 2003 May;10(9):717-36.

[4]. Kwon H J. Chemical Genomics-Based Target Mining and Validation of Biologically Active Small Molecules[J]. Frontiers in Medicinal Chemistry-Online, 2005, 2(1): 417-430.

[5]. Yin SQ, et al. The development of MetAP-2 inhibitors in cancer treatment. Current medicinal chemistry. 2012;19(7):1021-35. [Content Brief]

[6]. Sendzik M, et al. Design and synthesis of beta-amino-alpha-hydroxy amide derivatives as inhibitors of MetAP2 and HUVEC growth. Bioorganic & medicinal chemistry letters. 2004 Jun 21;14(12):3181-4.

[7]. Bradshaw, R. A. (2004). Methionine aminopeptidase 2 inhibition: antiangiogenesis and tumour therapy. Expert Opinion on Therapeutic Patents, 14(1), 1-6.